scholarly journals Validation of lactate level as a predictor of early mortality in acute decompensated heart failure patients who entered intensive care unit

2015 ◽  
Vol 65 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Tomoharu Kawase ◽  
Mamoru Toyofuku ◽  
Tasuku Higashihara ◽  
Yousaku Okubo ◽  
Lisa Takahashi ◽  
...  
PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0251505
Author(s):  
Masato Kanda ◽  
Kazuya Tateishi ◽  
Atsushi Nakagomi ◽  
Togo Iwahana ◽  
Sho Okada ◽  
...  

The management of acute decompensated heart failure often requires intensive care. However, the effects of early intensive care unit/coronary care unit admission on activities of daily living (ADL) in acute decompensated heart failure patients have not been precisely evaluated. Thus, we retrospectively assessed the association between early intensive care unit admission and post-discharge ADL performance in these patients. Acute decompensated heart failure patients (New York Heart Association I–III) admitted on emergency between April 1, 2014, and December 31, 2018, were selected from the Diagnosis Procedure Combination database and divided into intensive care unit/coronary care unit (ICU) and general ward (GW) groups according to the hospitalization type on admission day 1. The propensity score was calculated to create matched cohorts where admission style (intensive care unit/coronary care unit admission) was independent of measured baseline confounding factors, including ADL at admission. The primary outcome was ADL performance level at discharge (post-ADL) defined according to the Barthel index. Secondary outcomes included length of stay and total hospitalization cost (expense). Overall, 12231 patients were eligible, and propensity score matching created 2985 pairs. After matching, post-ADL was significantly higher in the ICU group than in the GW group [mean (standard deviation), GW vs. ICU: 71.5 (35.3) vs. 78.2 (31.2) points, P<0.001; mean difference: 6.7 (95% confidence interval, 5.1–8.4) points]. After matching, length of stay was significantly shorter and expenses were significantly higher in the ICU group than in the GW group. Stratified analysis showed that the patients with low ADL at admission (Barthel index score <60) were the most benefited from early intensive care unit/coronary care unit admission. Thus, early intensive care unit/coronary care unit admission was associated with improved post-ADL in patients with emergency acute decompensated heart failure admission.


2009 ◽  
Vol 73 (12) ◽  
pp. 2264-2269 ◽  
Author(s):  
Masayuki Yamaji ◽  
Takayoshi Tsutamoto ◽  
Toshinari Tanaka ◽  
Chiho Kawahara ◽  
Keizo Nishiyama ◽  
...  

2008 ◽  
Vol 15 (4) ◽  
pp. 355-362 ◽  
Author(s):  
Thomas A. Tallman ◽  
W. Frank Peacock ◽  
Charles L. Emerman ◽  
Margarita Lopatin ◽  
Jamie Z. Blicker ◽  
...  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
Y Watanabe ◽  
Y Nara ◽  
H Hioki ◽  
H Kawashima ◽  
A Kataoka ◽  
...  

Abstract Background Tolvaptan exerts potent diuretic effects in heart failure patients without hemodynamic instability. Nonetheless, its clinical efficacy for acute decompensated heart failure (ADHF) due to severe aortic stenosis (AS) remains unclear. This study aimed to evaluate the short-term effects of tolvaptan in ADHF patients with severe AS. Methods The LOw-Dose Tolvaptan (7.5 mg) in Decompensated Heart Failure Patients with Severe Aortic Stenosis (LOHAS) registry is a multicenter (7 centers) prospective registry that assessed the short-term effects of tolvaptan in subjects hospitalized for ADHF with severe AS. A total of 59 subjects were enrolled between September 2014 and December 2017. The primary endpoints were changes in body weight and fluid balance measured daily from baseline up to 4 days. Results The median [interquartile range] patient age and aortic valve area were 85.0 [81.0–89.0] years and 0.58 [0.42–0.74] cm2, respectively. Body weight continuously decreased, and fluid balance was maintained from baseline to day 4 (p&lt;0.001, p=0.194, respectively). Median serum B-type natriuretic peptide concentration significantly decreased from 910.5 to 740.0 pg/mL by day 4 (p=0.002). However, systolic blood pressure and heart rate were non-significantly changed (p=0.250, p=0.656, respectively). Hypernatremia (&gt;150 mEq/L) and worsening renal function occurred in 2 (3.4%) and 4 (6.8%) patients, respectively. Conclusions Short-term treatment with low-dose tolvaptan is safe and effective, providing stable hemodynamic parameters in patients with ADHF and severe AS. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): This research was supported by Otsuka Pharmaceutical Co., Ltd.


2010 ◽  
Vol 12 (4) ◽  
pp. 404-410 ◽  
Author(s):  
Claes-Håkan Bergh ◽  
Bert Andersson ◽  
Ulf Dahlström ◽  
Kolbjorn Forfang ◽  
Matti Kivikko ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document